Phase II
The vaccine will be dosed at a 30-microgram level with a two-dose regimen. The vaccine is an mRNA product, with the mRNA encoding for the SARS-CoV-2 full length spike glycoprotein (S).
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 27, 2020.
It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.
The company posted Phase II data that showed its experimental asset fosmanogepix demonstrated a treatment success rate of 80%.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 24, 2020.
Francis Collins, the director of the NIH, told STAT they were “really well-powered, rigorously designed clinical trials.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 22, 2020.
CanSino Biologics, along with China’s military research unit, reported early data on its Phase II trial for its COVID-19 vaccine, Ad5-nCOV.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 20, 2020.
It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look.
PRESS RELEASES